SCHEMBL20137111

SCHEMBL20137111

Cc1ccc(Br)c(O)c1Cl

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.37
CHRM1 P11229 1/20 0.37
ALOX15 P16050 1/20 0.37
MAOA P21397 1/20 0.37
TBXA2R P21731 1/20 0.37
ADRA1A P35348 1/20 0.37
HTR2B P41595 1/20 0.37
ALDH1A1 P00352 7/20 0.35
AR P10275 1/20 0.34
MEN1 O00255 4/20 0.33
MAPT P10636 4/20 0.33
HPGD P15428 4/20 0.33
KMT2A Q03164 4/20 0.33
GAA P10253 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
LMNA P02545 1/20 0.32
PTGS1 P23219 2/20 0.31
ALOX5 P09917 1/20 0.31
PTGS2 P35354 1/20 0.31
TRPA1 O75762 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL901691 0.79 ALDH1A1 (0.48) CYP3A4CHRM1ALOX15MAOATBXA2R
SCHEMBL5273045 0.77 ALDH1A1 (0.38) CYP3A4CHRM1ALOX15MAOATBXA2R
SCHEMBL11611309 0.75 ALDH1A1 (0.38) CYP3A4ALOX15ALDH1A1MEN1MAPT
SCHEMBL69141 0.75 CYP3A4 (0.46) CYP3A4ALOX15ALDH1A1ARMEN1
SCHEMBL4448667 0.75 ALDH1A1 (0.36) CYP3A4ALDH1A1
SCHEMBL221824 0.75 TRPA1 (0.39) CYP3A4ALOX15ALDH1A1MEN1MAPT
SCHEMBL16815458 0.75 CYP3A4 (0.46) CYP3A4ALDH1A1ARMEN1MAPT
SCHEMBL3684343 0.75 TRPA1 (0.44) CYP3A4CHRM1ALOX15MAOATBXA2R
SCHEMBL3032868 0.75 ALDH1A1 (0.41) CYP3A4CHRM1ALOX15MAOATBXA2R
SCHEMBL14660455 0.71 POLB (0.41) ALOX15ALDH1A1ARMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110267963-B MAGL inhibitors H.隆德贝克有限公司 2022-04-01 CN disclosed
EP-3541821-A1 MAGL INHIBITORS Abide Therapeutics, Inc. (US) 2019-09-25 EP disclosed
US-10093635-B2 MAGL inhibitors ABIDE THERAPEUTICS, INC. (US) 2018-10-09 US disclosed
WO-2018093947-A1 MAGL INHIBITORS ABIDE THERAPEUTICS, INC. (US) 2018-05-24 WO disclosed
WO-2018093947-A1 MAGL INHIBITORS ABIDE THERAPEUTICS, INC. (US) 2018-05-24 WO disclosed
US-20180134674-A1 MAGL INHIBITORS H. LUNDBECK A/S (DK) 2018-05-17 US disclosed
US-20180134674-A1 MAGL INHIBITORS H. LUNDBECK A/S (DK) 2018-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180134674-A1 MAGL INHIBITORS MAG, MAGI3, MGLL CYP3A4 4468/4885CHRM1 2214/4885ALOX15 1908/4885
US-10093635-B2 MAGL inhibitors MAG, MAGI3, MGLL CYP3A4 4468/4885CHRM1 2214/4885ALOX15 1908/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.